Avalo Therapeutics AVTX
NASDAQ AVTX
$19.23 +0.23 (+1.18%)
As of: Sep 4, 2026 · 1:32 PM EDT

Avalo Therapeutics (AVTX) Non Operating Interest Expenses (2014 - 2015)

Analysis

Avalo Therapeutics (AVTX) Non Operating Interest Expenses (2014 - 2015) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.27 Bn 131.42 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.55 Bn 77.56 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.45 Bn 58.27 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.73 Bn 52.59 Bn 52.00 Mn -
5 Revolution Medicines 44.08 Bn 44.08 Bn - 23.78 Mn
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.14 Bn 31.84 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.44 Bn 27.60 Bn - 93.62 Mn
9 Insmed 27.32 Bn 26.16 Bn 358.27 Mn 20.27 Mn
10 Avalo Therapeutics 838.25 Mn 838.25 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2015 197,470.00
Sep 30, 2014 189,679.00